Skip to content

From Early Discovery to Late-Phase Manufacturing:

Synbio Technologies and Porton Advanced Offer End-to-End Solutions for Cell and Gene Therapy

Monmouth Junction, New Jersey, May 8, 2023 – Synbio Technologies and Porton Advanced are proud to announce a new partnership aimed at providing more streamlined, end-to-end solutions for cell and gene therapy (CGT) clients. The partnership combines the expertise of Synbio Technologies and Porton Advanced to improve success rates for CGT by linking upstream molecular optimization to downstream CMC process and manufacturing optimization.

The partnership takes a proactive approach by integrating upstream molecular design with CMC to deliver more efficient and effective cell and gene therapy solutions. This involves mapping key components of services, including upstream research solutions and later-stage development, submission, and manufacturing to optimally connect molecular design and synthesis with process development and manufacturing. By doing so, the partnership ensures that each step of the process is carefully aligned to achieve the best possible outcomes for clients, from initial discovery to final manufacturing, resulting in better solutions for patients.

Synbio Technologies, a leading provider of design, synthesis, and optimization services of nucleic acid molecules for research and CGT development, will provide codon optimization, sequence optimization, vector, antibody, and mRNA design, complex gene synthesis, vector construction, protein and cell engineering, strain and cell development, while leveraging proprietary AI-aided synthesis technology that produces smarter genes in spite of their complexity. Porton Advanced will provide dedicated CGT CDMO end-to-end services from plasmid, viral vectors to cellular product process development and GMP manufacturing, as well as R&D of novel viral and non-viral based delivery systems and platforms.

The company developed proprietary viral vector platforms that cover LVV and AAV CMC, and other research-stage platforms aimed at improving tissue specificity, enhanced payload, and ease of manufacturing. A close cooperation between the technical and business development teams at Synbio Technologies and Porton Advanced will ensure that clients receive high-quality services that are seamlessly integrated and delivered with confidence.

The goal of the partnership is to provide end-to-end solutions for gene and cell therapy customers, from base pair to bedside. By integrating research services, development, and GMP manufacturing, the partnership aims to streamline the discovery and development of cell and gene therapies, delivering better understanding and peace of mind for clients at both the research and development stages. The teams at Synbio Technologies and Porton Advanced work closely with clients to identify critical factors at every stage of the process, from molecular synthesis to PD and manufacturing. This proactive approach enables the partnership to respond quickly and effectively to market demands and provide cohesive solutions that meet the unique needs of each client. By linking upstream molecular synthesis and optimization to downstream PD and cGMP manufacturing optimization, the partnership offers improved rates for druggability. Through this partnership, Synbio Technologies and Porton Advanced are committed to providing unparalleled expertise, service, and support to their clients, helping them to achieve their gene and cell therapy goals.


Synbio Technologies is a leading biotechnology company that utilizes AI-aided gene synthesis to provide clients with smarter genes. By leveraging cutting-edge technology, Synbio Technologies helps its clients develop better products with fewer challenges. Their commitment to innovation and customer satisfaction has made them a trusted partner in the biotech industry.

 Porton Advanced Solutions (Porton Advanced) is a Cell and Gene Therapy (CGT) CDMO. They provide end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services to meet clients’ therapeutic product needs at pre-clinical, clinical, and commercial stages.

Synbio x Porton